Amryt Optimistic For Year Ahead Despite Filsuvez CRL Setback
Anticipates $260m-$270m Revenue In 2022
The rare disease firm hopes continued growth of key products Myalept and Mycapssa will bolster 2022 revenues as it contends with a US regulatory delay for Filsuvez.
